“If positive, the IDEAL study could support a label update and expand the second-line PBC addressable population.”

In context

“ial best-in-disease BCMA CAR T, in December. Our acquisition of Arcellx, which closed on April 28, reflects our conviction in the potential of anitocel as a differentiated option for patients with multiple myeloma. Given the significant opportunity in fourth line as well as earlier lines of therapy, we believe anitocel could become a foundational therapy for multiple myeloma, driving growth in our cell therapy business in 2027 and beyond. The Arcellx platform will leverage Kite's industry-leading capabilities and could further strengthen our future in oncology and inflammation. In liver disease, Libdelzi revenue for second-line primary biliary cholangitis more than tripled year-over-year. We are expecting an update from our Phase 3 IDEAL study for Libdelzi in the second half of this year. If positive, the IDEAL study could support a label update and expand the second-line PBC addressable population. Additionally, we expect a regulatory decision and potential U.S. launch of Hepcludex for chronic hepatitis delta virus infection later this quarter. In inflammation, the potential acquisition of Oral Medicines will add to our portfolio with gamgurtamig, a BCMA-CD3 T cell engager in multiple B cell-driven autoimmune diseases. We will also share Phase 2 updates for our oral IRAK4 inhibitor and oral alpha4beta7 small molecule this year. These commercial and clinical updates demonstrate the strength of our execution today underpinned by our continued commitment to financial discipline. As we look to the remainder of 2026, we see many exciting opportunities to further expand our impact on the patients and communities we aim to serve. With that, I will hand it over to Joanna. Johanna Mercier: T”